Regulatory Action Against HCG Hospital Over Trial Violations
India's drug regulatory authority has barred the Kalinga Rao Road (KRR) unit of HCG Hospital in Bengaluru from conducting any new clinical trials for a period of 24 months. The action follows findings of serious safety violations at the facility, including failure to report serious adverse events (SAEs), casualties, and conflicts of interest during clinical trials conducted under the New Drugs and Clinical Trials Rules, 2019.
Details of the Violations
In a letter dated June 12, 2026, the Drugs Controller General of India (DCGI) outlined that the KRR unit had failed to comply with mandatory reporting requirements. Specifically, the hospital did not report serious adverse events and deaths that occurred during the trials, nor did it disclose conflicts of interest among investigators. These omissions violate the regulatory framework designed to protect trial participants and ensure data integrity.
Impact on Ongoing and Future Trials
The debarment order, issued under the provisions of the New Drugs and Clinical Trials Rules, 2019, prohibits the HCG Hospital KRR unit from enrolling new participants or initiating any new clinical trial protocols for the next two years. However, the order allows the continuation of existing trials where participants are already enrolled, provided they are monitored closely and all reporting requirements are met. The hospital has been directed to submit a corrective action plan to the Central Drugs Standard Control Organisation (CDSCO) within 30 days.
Background and Regulatory Concern
HCG Hospital is a prominent healthcare provider in Bengaluru, known for its oncology and multi-specialty services. The KRR unit has been involved in several clinical trials for new drugs and therapies. The CDSCO's action underscores the regulator's increasing vigilance over clinical trial conduct in India, particularly after several high-profile cases of non-compliance in recent years. According to sources, the violations at HCG came to light during a routine inspection by the CDSCO earlier this year.
Hospital Response
HCG Hospital has not yet issued an official statement on the debarment. However, a hospital official, speaking on condition of anonymity, said: "We are reviewing the order and will take all necessary steps to address the concerns raised by the regulator. Patient safety remains our top priority." The hospital is expected to submit its corrective action plan shortly.
Broader Implications for Clinical Trials in India
This debarment is likely to have ripple effects across the clinical research landscape in India. The country has been striving to improve its regulatory compliance to attract more global clinical trials, which have declined in recent years due to concerns over ethical violations and regulatory hurdles. The CDSCO's strict action against HCG sends a clear message that non-compliance will not be tolerated. Industry experts suggest that other hospitals and research sites may now face increased scrutiny, potentially leading to more audits and enforcement actions.
The 24-month ban could also impact HCG's reputation and its ability to partner with pharmaceutical companies for future research. However, the hospital may resume trials after the ban period, subject to a satisfactory compliance review.
